How to Assess Immunotherapy Toxicity using NHPs
The safety of immunotherapies is a major clinical concern which needs to be addressed early in preclinical immunotherapy development. Appropriate models are needed which share close immunological homology with humans, and have an intact immune system, to test for cross-reactivity and screen for potential immunotoxicity.
This White Paper explores NHPs as a valuable early-stage preclinical platform for non-GLP exploratory toxicology studies. These highly translatable models provide a reliable method to assess immunotherapy safety, and de-risk future clinical trials.
Download This White Paper to Understand:
- That non-GLP exploratory NHP toxicology studies are rapid, cost effective, and generate robust data to guide future GLP work and clinical studies
- How to design and implement flexible non-GLP NHP exploratory toxicology studies to answer multiple developmental questions, such as dosing regimen and immunogenicity endpoints
- The NHP model features that provide an ideal preclinical model for elucidating immune-related toxicity